![](https://pmlive.com/wp-content/uploads/2024/02/Ipsen_headquarters.jpg)
Ipsen gains ex-US rights to Day One’s brain cancer therapy in deal worth over $460m
Ipsen has announced that it has entered into a global partnership worth over $460m with Day One to commercialise its monotherapy to treat common paediatric brain tumours. As part of the deal, Ipsen will obtain all ex-US global regulatory and commercial …